CD7

Across TCGA pan-cancer cohorts, CD7 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CD7 data layer compared with 28 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher CD7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CD7 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

OV, BLCA, and SKCM are the cancer types where CD7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.021	0.844	<.001	36	view →
BLCA	OS	Median	All	0.141	0.687	.003	21	view →
SKCM	OS	Median	II,III,IV	0.776	0.305	.030	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CD7–OV (OS)

Open the OV breakdown →